Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Junshi Biosciences Licenses Anti-IL-17A Antibody Roconkibart to Fosun Wanbang for Greater China – $1.34B Deal Secures Commercialization of Phase III-Ready Psoriasis Therapy

Fineline Cube Jul 2, 2026
Company Deals Digital

Insilico Medicine and Takeda Launch $600M Strategic AI Drug Discovery Collaboration – Pharma.AI Platform to Drive Candidate Identification for High-Potential Therapeutic Targets

Fineline Cube Jul 2, 2026
Company Deals

Nona Biosciences and Lonza Forge Strategic Alliance to Develop Best-in-Class Blood-Brain Barrier Penetration Technology for CNS Therapeutics

Fineline Cube Jul 2, 2026
Company Deals

Ipsen to Acquire Memo Therapeutics for €200M Plus Milestones, Gaining Phase II BK Virus Antibody Potravitug for Transplant Nephropathy

Fineline Cube Jul 2, 2026
Company Deals

Ribo Life Science Achieves First Milestone in siRNA Collaboration with Madrigal for MASH Therapeutics

Fineline Cube Jul 2, 2026
Policy / Regulatory

China’s CDE Unveils 108th Batch of Reference Preparations for Generic Drug Evaluation, Adds 28 New Drugs

Fineline Cube Jun 29, 2026
Company Drug

Hangzhou Adamerck’s Aom0498 Receives NMPA Approval as China’s First Homegrown Neuromuscular Blockade Reversal Agent – Completing Decade-Long National Innovation Program

Fineline Cube Jul 2, 2026
Company Drug

Jingxin Pharmaceutical Secures NMPA Approval for China’s First Generic Cariprazine in Schizophrenia – Capturing Market Opportunity as Reference Product Remains Unlaunched

Fineline Cube Jul 2, 2026
Company Drug

Anhui Anke’s Allogeneic CAR-T Therapy UTAA09 Approved for r/r B-ALL Trials

Fineline Cube Apr 25, 2025

China-based Anhui Anke Biotechnology (Group) Co., Ltd (SHE: 300009) announced that its joint venture with...

Company Drug

Juventas Cell Therapy’s CNCT 19 Gains NMPA Approval for Refractory Lupus Nephritis

Fineline Cube Apr 25, 2025

China-based Juventas Cell Therapy Ltd announced that its chimeric antigen receptor (CAR)-T cell therapy, inaticabtagene...

Company Drug

TYK Medicines Submits Pre-NDA Package for Asandeutertinib in NSCLC Brain Metastasis

Fineline Cube Apr 25, 2025

China-based TYK Medicines, Inc. (HKG: 2410) announced the formal submission of a pre-NDA communication package...

Company Medical Device

MicroPort Scientific’s MRI-Conditional ALIZEA Hybrid Pacing System Secures CE Certification

Fineline Cube Apr 25, 2025

Shanghai-based medical device giant MicroPort Scientific Corp. (HKG: 0853), through its French subsidiary MicroPort Cardiac...

Company Drug

AbbVie Files BLA for TrenibotE in Moderate to Severe Glabellar Lines Treatment

Fineline Cube Apr 25, 2025

US-based AbbVie (NYSE: ABBV) announced that it has filed a Biologics License Application (BLA) with...

Company Drug

GenFleet’s KRAS G12D Inhibitor GFH375/VS-7375 Gains FDA Trial Approval

Fineline Cube Apr 25, 2025

Shanghai-based biotech GenFleet Therapeutics announced that its GFH375/VS-7375, an oral KRAS G12D inhibitor co-developed with...

Company Deals Drug

Innate Pharma and Sanofi Restructure 2016 Research Agreement on CD123 ANKET Drug

Fineline Cube Apr 25, 2025

France-based Innate Pharma SA has announced a significant adjustment to its 2016 research and licensing...

Company Medical Device

Medtronic Submits 510(k) Applications for Interoperable Diabetes Management System

Fineline Cube Apr 25, 2025

US-Irish firm Medtronic plc (NYSE: MDT) has submitted twin 510(k) applications to the U.S. Food...

Company Medical Device

Thermo Fisher Announces $2 Billion US Investment to Strengthen Life Sciences Infrastructure

Fineline Cube Apr 25, 2025

US-based life sciences giant Thermo Fisher Scientific Inc. (NYSE: TMO) has announced a USD 2...

Company Deals

Merck KGaA Nears Completion of $3.5 Billion Acquisition of SpringWorks Therapeutics

Fineline Cube Apr 25, 2025

German pharmaceutical major Merck KGaA (ETR: MRK) is reportedly nearing the completion of its acquisition of...

Company Deals

CN Bio and Pharmaron Partner to Validate and Expand OOC Technology Applications

Fineline Cube Apr 25, 2025

CN Bio, a UK-based provider of Organ-on-a-chip (OOC) systems and solutions, has entered into a...

Company

Gan & Lee Pharmaceuticals Reports 417 Million USD Revenue and 80.75% Profit Surge in 2024

Fineline Cube Apr 25, 2025

Gan & Lee Pharmaceuticals (SHA: 603087) reported revenues of RMB 3.045 billion (USD 417 million)...

Company Drug

Hepalink Secures SAHPRA Approval for Ivenoxin in South Africa

Fineline Cube Apr 25, 2025

Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (SHE: 002399, HKG: 9989) has announced that it has...

Company Drug

Akeso’s Penpulimab Gains FDA Approval for Nasopharyngeal Carcinoma Treatment

Fineline Cube Apr 25, 2025

China-based Akeso, Inc. (HKG: 9926) announced that it has received marketing approval from the US...

Company

Sanofi Reports Q1 Sales Growth Driven by Dupixent and New Product Launches

Fineline Cube Apr 25, 2025

French pharmaceutical giant Sanofi (NASDAQ: SNY) released its Q1 2025 financial results, reporting global net...

Company Deals

Shineco Inc. Announces Acquisition of InfiniClone for Regenerative Medicine Expansion

Fineline Cube Apr 24, 2025

US-based Shineco Inc. (NASDAQ: SISI) announced that its subsidiary Shineco Life Sciences Group Hong Kong...

Company Deals

Shenzhen Core Medical Closes Series D Round to Advance Miniaturized Artificial Hearts

Fineline Cube Apr 24, 2025

Shenzhen Core Medical Technology Co., Ltd, a developer of mechanical circulation assist systems, has reportedly...

Company Drug

Doer Biologics Begins Phase II Study of DR10624 for Steatotic Liver Disease

Fineline Cube Apr 24, 2025

China-based Zhejiang Doer Biologics Co., Ltd has announced the first patient dosing in a Phase...

Company Deals Drug

Boehringer Ingelheim Partners with Tessellate Bio on ALT Cancer Therapies

Fineline Cube Apr 24, 2025

Boehringer Ingelheim (BI), a German pharmaceutical leader, has entered into a strategic collaboration and global...

Company Deals

Genentech Collaborates with Repertoire Immune Medicines on Autoimmune Disease Therapies

Fineline Cube Apr 24, 2025

Genentech, a subsidiary of Swiss pharmaceutical leader Roche (SWX: ROG, OTCMKTS: RHHBY) , announced a collaboration...

Posts pagination

1 … 195 196 197 … 690

Recent updates

  • Hangzhou Adamerck’s Aom0498 Receives NMPA Approval as China’s First Homegrown Neuromuscular Blockade Reversal Agent – Completing Decade-Long National Innovation Program
  • Junshi Biosciences Licenses Anti-IL-17A Antibody Roconkibart to Fosun Wanbang for Greater China – $1.34B Deal Secures Commercialization of Phase III-Ready Psoriasis Therapy
  • Jingxin Pharmaceutical Secures NMPA Approval for China’s First Generic Cariprazine in Schizophrenia – Capturing Market Opportunity as Reference Product Remains Unlaunched
  • TransThera Completes Patient Enrollment in Global Phase III Trial of Tinengotinib for Advanced Cholangiocarcinoma – Multi-Kinase Inhibitor Backed by Multiple Regulatory Designations
  • TransThera Advances Phase II Trial of Selective BTK Inhibitor TT-01488 with Anti-CD20 Antibodies for Mantle Cell Lymphoma – Novel Non-Covalent Approach Shows Enhanced Safety Profile
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Hangzhou Adamerck’s Aom0498 Receives NMPA Approval as China’s First Homegrown Neuromuscular Blockade Reversal Agent – Completing Decade-Long National Innovation Program

Company Deals

Junshi Biosciences Licenses Anti-IL-17A Antibody Roconkibart to Fosun Wanbang for Greater China – $1.34B Deal Secures Commercialization of Phase III-Ready Psoriasis Therapy

Company Drug

Jingxin Pharmaceutical Secures NMPA Approval for China’s First Generic Cariprazine in Schizophrenia – Capturing Market Opportunity as Reference Product Remains Unlaunched

Company Drug

TransThera Completes Patient Enrollment in Global Phase III Trial of Tinengotinib for Advanced Cholangiocarcinoma – Multi-Kinase Inhibitor Backed by Multiple Regulatory Designations

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.